Apogee Therapeutics Readies Zumi for Phase 3 With Blackstone Backing

Apogee Therapeutics NASDAQ: APGE executives said the company is preparing to move its lead drug candidate, zumilokibart, into Phase 3 testing later this year after reporting Phase 2b data in atopic dermatitis and securing a major financing agreement with Blackstone.

MarketBeat • Jun 4, 2026

Apogee Therapeutics, Inc. (APGE) Discusses Positive Part B Results From Phase 2 APEX Trial of Zumilokibart in Atopic Dermatitis Transcript

Apogee Therapeutics, Inc. (APGE) Discusses Positive Part B Results From Phase 2 APEX Trial of Zumilokibart in Atopic Dermatitis Transcript

Seeking Alpha • Jun 1, 2026

Apogee Therapeutics lines up $1.3B strategic financing for zumilokibart program

Apogee Enterprises (NASDAQ:APOG) has entered a strategic financing collaboration with Blackstone Life Sciences for up to $1.3 billion in non-dilutive capital, combining up to $800 million in synthetic royalty financing with as much as $500 million in senior corporate debt, giving the immunology developer runway to advance Phase 3 development and potential commercialization of its lead candidate zumilokibart. The financing structure pairs royalty-based capital tied to future product revenue with senior debt capacity.

Proactive Investors • May 28, 2026

Apogee Therapeutics to Participate in Upcoming June Conferences

SAN FRANCISCO and BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate at the following investor conferences.

GlobeNewsWire • May 28, 2026

Apogee Therapeutics: Charging Toward Pivotal Eczema Trial With Extended Dosing

Apogee Therapeutics, Inc. remains a Buy, driven by zumilokibart's potential in atopic dermatitis and recent positive Phase 2b data. Zumilokibart's efficacy matches leading biologics, with the key differentiator being 2–4 annual doses, pending maintenance data in 2025. The Blackstone collaboration secures up to $1.3B in funding, eliminating near-term dilution risk and supporting commercialization.

Seeking Alpha • May 28, 2026

Why Apogee Slipped On Its Dupixent-Rivaling Eczema Results

Apogee Therapeutics revealed mixed results for its experimental eczema treatment Wednesday, and the stock dropped.

Investors Business Daily • May 27, 2026

Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis

APEX Part B met all primary and secondary endpoints with high statistical significance; mid-dose zumilokibart planned to advance into Phase 3 trials in moderate-to-severe atopic dermatitis (AD) in 2H 2026

GlobeNewsWire • May 27, 2026

Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart

Up to $1.3 billion in flexible, non-dilutive capital, including up to $800 million of synthetic royalty and access of up to $500 million in senior corporate debt

GlobeNewsWire • May 27, 2026

Apogee secures up to $1.3 billion from Blackstone to advance eczema drug

Apogee Therapeutics said on Wednesday it secured a financing deal with Blackstone Life Sciences worth up to $1.3 billion to support ​late-stage development and potential commercialization of its experimental eczema drug, ‌zumilokibart.

Reuters • May 27, 2026

Apogee Therapeutics to Host Conference Call to Report Part B 16-Week Data from the Phase 2 APEX Trial of Zumilokibart in Patients with Moderate-to-Severe Atopic Dermatitis on May 27, 2026

SAN FRANCISCO and BOSTON, May 26, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced it will report Part B 16-week data from the Phase 2 APEX trial of zumilokibart on Wednesday, May 27, 2026. Following the announcement, the company will host a conference call and webcast at 8:00 a.m.

GlobeNewsWire • May 26, 2026